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Summary
An expert panel on the treatment of type B intramural haematoma (IMH) and penetrating atherosclerotic ulcer (PAU) consisting of cardiol-
ogists, cardiothoracic surgeons, vascular surgeons and interventional radiologists reviewed the literature to develop treatment algorithms
using a consensus method. Data from 46 studies considered relevant were retrieved for a total of 1386 patients consisting of 925 with IMH,
and 461 with PAU. The weighted mean 30-day mortality from IMH was 3.9%, 3-year aortic event-related mortality with medical treatment
5.4%, open surgery 23.2% and endovascular therapy 7.1%. In patients with PAU early and 3-year aortic event-mortality rates with open
surgery were 15.9 and 25.0%, respectively, and with TEVAR were 7.2 and 10.4%, respectively. According to panel consensus statements,
haemodynamic instability, persistent pain, signs of impending rupture and progressive periaortic haemorrhage in two successive imaging
studies require immediate surgical or endovascular treatment. In the absence of these complications, medical treatment is warranted,
with imaging control at 7 days, 3 and 6 months and annually thereafter. In the chronic phase, aortic diameter >55 mm or a yearly increase
≥5 mm should be considered indications for open surgery or thoracic endovascular treatment, with the latter being preferred. In compli-
cated type B aortic PAU and IMH, endovascular repair is the best treatment option in the presence of suitable anatomy.
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INTRODUCTION
Aortic intramural haematoma (IMH) is an entity belonging to the
spectrum of acute aortic syndrome (AAS) in which haemorrhage
occurs in the media of the aortic wall in the absence of a demon-
strable two-lumen ﬂow and primary intimal tear [1]. IMH is diag-
nosed in the presence of circular or crescentic thickening >5 mm of
the aortic wall in the absence of detectable blood ﬂow in the vessel
wall. The term penetrating aortic ulcer (PAU) describes the condi-
tion in which ulceration of an atherosclerotic lesion penetrates the
internal elastic lamina into the media [1]. PAU is considered to be a
disease of the intima (i.e. atherosclerosis), whereas aortic dissection
and its variant (IMH) are fundamentally diseases of the media.
Approximately 5–15% of AAS are diagnosed as IMH [2, 3] and 5% as
PAU. Symptoms of these entities are similar to those of aortic dis-
section and may be indistinguishable, although patients are less
likely to suffer from malperfusion syndrome. The main objective of
IMH and PAU treatment is to prevent aortic rupture or progression
to classic dissection. As type A IMH and PAU have a high, early risk
of complications and death with medical treatment alone, surgery
is usually indicated [4]. A conservative approach to uncomplicated
type B IMH such as antihypertensive treatment and watchful moni-
toring is currently preferred as it appears to be a safer strategy.
However, in some cases, the disease may still progress despite
optimal medical treatment. Notwithstanding some recommenda-
tions for endovascular repair of AAS [4–6], the indications in IMH
and PAU remain controversial, and the general approach is to treat
them like aortic dissection, even without scientiﬁc data. In the
American Heart Association guidelines published in 2010, these en-
tities were brieﬂy discussed in the context of three overlapping
aortic lesions: intimal defect without IMH, intimal defect with IMH
and IMH without an intimal defect. The course, morbidity and mor-
tality rates of each treatment remain unknown owing to the lack of
published large series. Although recent studies reported the beneﬁt
of thoracic endovascular aortic repair (TEVAR) in the treatment of
distal ascending aortic diseases [7], the present consensus will focus
only on type B lesions.
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This review of the literature was undertaken to identify current
morbidity and mortality rates in the medical, surgical and endo-
vascular treatment of IMH and PAU and, based on the results,
develop treatment algorithms using a consensus method.
METHODS
Literature search
The review of the literature was planned in accordance with
current guidelines for conducting comprehensive systematic
reviews. The literature search was implemented to identify studies
in peer-reviewed journals through a comprehensive search of
computerized databases including PubMed and Ovid Medline.
The search was inclusive up to February 2014 and limited to the
past 20 years. Search strings included ‘intramural hematoma and/
or penetrating aortic ulcer’ combined with the terms ‘endovascu-
lar treatment’, ‘surgical treatment’ and ‘medical treatment’. The
search was limited to articles on humans only with an abstract
available in English. After relevant studies were identiﬁed, add-
itional tangential searches were conducted using related article
links within PubMed. The assessment of studies for inclusion and
data extraction was conducted by one independent reviewer, and
validated by the panelists during the ﬁrst meeting. For clinical
outcomes, deﬁnitions provided by authors of the studies were
generally used. Only studies with speciﬁc analyses of type B in-
volvement were included. Early mortality and morbidity rates
were calculated perioperatively and 30 days postoperatively; late
mortality and morbidity rates were calculated as death or events
that occurred from Day 31 and beyond. Mortality related to aortic
events during the ﬁrst 3 years was speciﬁcally analysed to establish
a similar follow-up period among treatment groups.
Expert panel
An expert panel of seven leaders in the treatment of type B IMH
and PAU consisting of cardiologists, cardiothoracic surgeons,
vascular surgeons and interventional radiologists was organized
to participate in the consensus. All members represented the
Western European geographical area and were from referral
centres of aortic pathology. The members of the panel reviewed
the available literature and provided a consensus for the treatment
of these pathologies and tried to standardize deﬁnitions.
Consensus method
Current topics of debate in relation with the deﬁnition, predictive
factors of complicated course and treatment of both entities were
discussed from the results of published literature. Treatment algo-
rithms were created when general agreement among members
was reached. Focalized meetings were organized for the evalu-
ation of the initial disagreement issues to achieve unanimous ap-
proval after a re-review of the medical literature.
Statistical analysis
Literature data were stratiﬁed by pathology and type of treatment
(medical, TEVAR or open surgery). Number of cases, event rates
and weighted averages, obtained from the total of deaths with
respect to the total number of cases, are speciﬁed in each table.
Only comparisons of different treatment outcomes were com-
bined when treatments were applied in similar populations
(TEVAR vs open surgery).
SEARCH RESULTS
Aortic intramural haematoma
The literature search identiﬁed 157 potential publications. Of
these, 30 were considered relevant for the purposes of this review.
Several publications included clinical data on more than one treat-
ment modality. The majority of the publications with clinical data
were retrospective analyses. The 30 publications summarized
included a total of over 900 patients who suffered from type B
IMH; 731 patients underwent conservative medical management,
108 surgical treatment and 86 endovascular repair of the thoracic
aorta (TEVAR) with different commercial and homemade stent
grafts. Follow-up of patients was extensive and ranged up to 3
years.
Mortality in type B intramural haematoma. The weighted
average 30-day mortality rate in patients with type B IMH was 3.9%
and the overall late mortality rate in a mean follow-up of 36
months was 14.3% [8–26]. Predictors of mortality in the acute
phase, i.e. persistent pain, haemodynamic instability, maximum
aortic diameter (MAD) and periaortic haemorrhage were reported
in only a few articles [18, 27]. Late mortality in type B IMH was due
to aortic complications in at least 50% of cases; other causes were
cancer, infections or other cardiovascular diseases [15, 17, 23].
Evolution of intramural haematoma. Sixteen of the selected
publications contained data on IMH progression [10, 14–17, 19,
22, 23, 28–35]. Progression was deﬁned as classical or localized
dissection, impending rupture or aneurysm formation of the aorta.
In general, IMH is more likely to stabilize or regress than to progress
(58.5 vs 48.7%) at 1 year. The mean rate for progression to classic
dissection was 5.3%, to localized dissection or ulcer-like projection
(ULP) 25.3%, to rupture 3.9% and to aneurysm 26.6%. Mean rates for
stabilization, regression and resolution were: 11.1, 32.1 and 59.9%,
respectively. The morphological changes in IMH, particularly in the
ﬁrst 6 months, are very dynamic. Only nine studies distinguished
between classic and localized dissection; this difference is signiﬁcant
since the latter causes most of the ULP images.
Predictors of complications. In the acute phase, persistent
pain, haemodynamic instability, MAD, IMH wall thickness,
presence of ULPs, pleural effusion or haemomediastinum and
periaortic haemorrhage have been identiﬁed as predictors of
complications (Table 1). Most of these predictors may be deﬁned
by imaging techniques:
(i) MAD in the acute phase is one of the major predictors of pro-
gression in type B IMH [10, 27, 30, 36]. Patients with a MAD
>45 mm have a higher risk of dissection, regardless of the lo-
cation [17, 36].
(ii) Wall thickness has been described as a predictor of progres-
sion [17, 29, 30, 33]; however, this issue is controversial [23].
Sueyoshi et al. [30] proposed a cut-off ≥10 mm, although this
value varied considerably in the different series published
from 10 to 15 mm.
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(iii) The incidence of periaortic haemorrhage or pleural effusion
is higher in IMH than in aortic dissection; in some studies, this
incidence rate rose to 40% [23]. Some series-related pleural
effusion led to unfavourable prognosis in IMH [27, 29, 33, 37].
However, there are at least two mechanisms to explain this
ﬁnding, a leakage of blood from the aorta through microper-
forations, or a non-haemorrhagic exudate from aortic wall in-
ﬂammatory reaction [38, 39] owing to the proximity of the
IMH to the adventitia. The difference between the prognostic
value of each type of pleural effusion may explain the dis-
cordance in the medical literature.
(iv) ULP is a frequent ﬁnding in type B IMH, and its incidence rate
ranges from 20–60% of cases [15, 26, 32, 33, 37, 40–42]. It is
deﬁned as a localized blood-ﬁlled pouch protruding into the
haematoma of the aortic wall [32], with a wide communicat-
ing oriﬁce of more than 3 mm [43]. In most cases, ULPs result
from a localized dissection. The prognostic signiﬁcance of
ULP is unclear, and a discrepancy exists as to its real meaning
in the context of type B IMH. This speciﬁc complication will
be discussed in the treatment section.
Mortality and treatment strategies
Medical treatment. Mortality rates for patients with type B IMH
who received medical treatment were identiﬁed in 18 publications
[2, 9, 11–20, 22–26, 31]. Patients diagnosed with type B IMH were
initially treated medically with beta blockers and other anti-
hypertensive therapies. The mean mortality rate in the acute phase
for these patients was 3.4% and within 3 years that related to aortic
events was 5.4%.
Surgical treatment. Sixteen publications contained data
regarding the mortality rates of surgical treatment in IMH [2, 9,
11–14, 16–20, 23–26, 31]. Patients with type B IMH were treated
with open surgery when medical treatment failed and/or when
the IMH progressed to dissection, aneurysm or rupture. The
mortality rate in the acute phase was 16% and within 3 years that
for surgical treatment in type B IMH was 23.2%.
Endovascular treatment. Data on endovascular treatment for
IMH are scant. Mortality rates could be assessed from only nine
articles [2, 17, 21–23, 31, 44–46]. The mean mortality rate in
patients treated with TEVAR in the acute phase was 4.6% and
within 3 years of follow-up was 7.1%. Indications for endovascular
treatment are not well established; however, larger series
accepted invasive intervention in patients who showed signs of
aortic rupture or aortic enlargement (MAD ≥55 mm or rapid
enlargement of the affected aorta or ULP) during follow-up [15,
26]. In comparison with open surgery, fewer cases were treated in
the acute phase (84.6%).
Complications in TEVAR
Complications in the use of TEVAR in IMH treatment were similar
to those in other aortic diseases; however, endoleaks in the acute
phase might be more frequent than in other TEVAR indications
[47, 48]. Endoleaks and lesions of the intimal layer at the ends of
the device frequently necessitated reintervention [21, 44, 49].
Some groups pointed out the presence of complications second-
ary to lesions caused in the intimal layer when the ends of the
stent were placed in the aortic wall affected by the IMH [50]. Most
of these cases initiated the formation of pseudoaneurysms, which
required a new TEVAR [21, 50–53].
Penetrating aortic ulcer
Penetrating aortic ulcer is an entity deﬁned as a focal lesion that
ulcerates the intima and disrupts the internal elastic lamina of the
aortic wall [1]. There are two main aetiologies: PAUs and ULPs sec-
ondary to intimal rupture during IMH evolution. Clinical overlap
between PAU and ULP in past decades has provoked confusion
regarding frequency, prognosis and management of these entities.
PAU refers to an ulcerating atherosclerotic lesion that penetrates
the elastic lamina and may be surrounded by a localized haema-
toma (Fig. 1). In this literature review of PAU, articles are included
considering each author’s deﬁnition except when they use this
term in the context of a ULP secondary to an IMH complication.
Although the true prevalence of PAU is not fully known owing to
the clinical overlapping with ULP, previous studies suggested an
incidence rate of PAU in AAS ranging 2–11% [54, 55], and autopsy
series found nearly 5% of dissections originating from a PAU [56].
Mortality in penetrating atherosclerotic ulcer. Little is known
of the mortality risk of PAU. Some authors considered it to pose a
higher risk than classic aortic dissection. However, others reported
that disease progression is slow, with a low prevalence of acute
rupture. These discrepancies can be explained by differences in
patient selection, particularly when cases have an incidental
diagnosis or are secondary to AAS.
Predictors of complications. Spontaneous rupture of the aorta
in PAU is a rare condition in the absence of AAS or severe
progressive dilatation. However, in symptomatic patients, the risk of
complications may be high. Signiﬁcant predictors of aortic rupture
have been considered to be recurrent or refractory pain despite
medical treatment [31, 57–59], haemodynamic instability, periaortic
bleeding or signiﬁcant/progressive pleural effusion [31, 47],
association with IMH [31, 60] and large ulcer size. In some cases,
PAUs evolve with surrounding IMHs and in others with saccular
aneurysm formation [17, 61]. There is no consensus on ulcer size
cut-off values; however, growth rate and MAD at the site of the
lesion have been considered, as in other aortic entities [4, 47].
Treatment of PAU. Considerable controversy exists regarding
the natural history of penetrating ulcers and, accordingly, the
indications for open surgical or endovascular treatment. A number
of authors reported satisfactory results with a conservative
Table 1: High-risk features of type B IMH based on the
literature reviewed
High-risk feature Cut-off or sign of
complicated evolution
Age (years) >70 [15, 36]
Initial aortic diameter (mm) >45 [17, 36]
Mean aortic diameter growth rate (mm/year) ≥5 [4, 6]
Wall thickness of involved segment (mm) ≥10 [30]
Pleural effusion Presence [27, 29]
Aortic ulcer Presence [15, 26]
Ulcer-like projection
IMH: intramural haematoma.
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approach to PAU [11, 62]. However, in most of those reports, PAU
were ULP in the context of IMH [48, 60]. Nevertheless, most authors
suggested that surgical intervention with grafting of the affected
area was the treatment of choice owing to a possible malignant
course [31]. Most patients presenting PAU may not be candidates
for conventional surgery owing to their general status or signiﬁcant
comorbidities [52]. Conventional surgery for PAU was associated
with a mortality rate of 15.9% [31, 55, 60–65]. It is obvious that
patients undergoing surgery for PAU are the ones with a negative
selection bias as the natural course of their disease warrants
treatment but endovascular therapy is not feasible. As patients
develop a PAU as a result of a severe systemic obliterative process,
they are usually affected by any of several kinds of symptomatic
obliterative arteriopathy limiting the success of surgical therapy. It
remains to the individual clinical situation as well as to the
estimation of the treating physician to determine a conservative
option if the operative risk is deemed unacceptably high.
As PAU is commonly observed as a segmental localized wall
lesion, it is an ideal target for endovascular stent grafting. Early
mortality in TEVAR is estimated to be 7.2% [48, 66–74]. The pres-
ence of associated IMH may increase the risk of treatment failure,
aortic rupture or aorta-related death [75], thereby highlighting the
need for careful planning, prudent balancing of the beneﬁts of a
possible delayed treatment to avoid fragility of the affected aortic
wall and other complications such as leaks, strokes etc. Moreover,
in one of the larger series published, Geisbüsch et al. [48] reported
a total of nine primary (19%: 4% of type I endoleak, 13% of type II
endoleak and 2% of type IV endoleak) and two secondary (4%: 2%
of type I endoleak and 2% of type IV endoleak) endoleaks among
48 patients. Reintervention was necessary in 4 of these 11 endo-
leaks (36%). Owing to the occurrence of secondary endoleaks,
close life-long follow-up was recommended in these patients [47].
In Table 2, the suggested indications for stent-graft repair are
deﬁned, based on the medical literature reviewed.
DISCUSSION AND PANEL CONSENSUS
Considerable controversy exists regarding the natural history of
these diseases and, consequently, the indication for open surgery
or TEVAR. Recent published guidelines [4] and a task force [6] dis-
cussed the three overlapping aortic lesions: intimal defect without
IMH, intimal defect with IMH and IMH without an intimal defect.
Thus, no speciﬁc recommendations were provided for the man-
agement in acute, subacute or chronic phases of these different
entities or, more speciﬁcally, IMH complicated by ULP versus PAU
surrounded by IMH.
Medical treatment was indicated in patients with an uncompli-
cated course, whereas endovascular or surgical therapy was gen-
erally considered in complicated cases. This issue is particularly
important for understanding the obtained results and the subse-
quent recommendations of the expert panel. The strength of pro-
posals provided by this document is limited because of the large
heterogeneity among studies and the absence of randomized
trials comparing TEVAR, with open surgery and medical therapy.
Aortic intramural haematoma
Results of the literature review showed that type B IMH presented
a low mortality rate in the acute phase. However, persistent pain
despite medical treatment, haemodynamic instability, MAD >55
mm and signiﬁcant periaortic haemorrhage are predictors of
acute-phase mortality. In these cases, invasive treatment is indi-
cated. The mortality rate in acute phase in complicated cases
treated with open surgery was 16% and with TEVAR 4.6%.
Figure 1: (A) CT image of an intramural haematoma in the descending thoracic aorta at the diagnosis of the acute aortic syndrome. (B) Development of two ulcer-like
projections in the same patient at sixth months CT control (black arrows). (C) Penetrating atherosclerotic ulcer in the aortic arch. Signiﬁcant atherosclerosis and calciﬁ-
cation of the borders of the lesion (black arrows) with deformation of the external morphology of the vessel.
Table 2: High-risk features of type B PAU based on the
medical literature reviewed and recommendations for
invasive treatment
High-risk feature Indication
Symptomatic patient Symptoms despite medical treatment
[31, 57–59]
Asymptomatic patient
Pleural effusion Increase in pleural effusion [31, 47]
IMH-associated Presence of IMH [31, 47]
Initial PAU depth and
diametera
Large initial PAU depth (>10 mm) and
diameter (>20 mm) or high growth rate
size [31]
aControversial: not fully accepted, and cut-off value unclear.
IMH: intramural haematoma; PAU: penetrating atherosclerotic ulcer.
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However, these results may be biased owing to a tendency to
report positive results of a novel technique. The main limitation of
TEVAR in the acute phase is the high risk of secondary endoleaks
and intimal ruptures or pseudoaneurysm formation, when the
ends of the device are placed in the aortic wall affected by the
IMH [21, 44, 49], secondary to mechanical stress and the pulsatile
force acting on the stent ends [21, 50]. Sufﬁcient landing zones, a
minimum of 15 mm from the affected zone [60], are necessary
and, in some cases, a considerable portion of the proximal and
distal aorta needs to be covered [76]. Nevertheless, as aortic
coverage length represents an independent predictor for spinal
cord ischaemia, the risk of occlusion of segmental arteries is
increased and should be prevented whenever possible. Usually,
10–20% oversizing with respect to the aortic diameter is recom-
mended in order to promote aneurysm sac exclusion and avoid
stent-graft migration. However, in a fragile aortic wall, such as in
an IMH, a compromise between stent-graft ﬁxation and the risk of
iatrogenic dissection may indicate the use of inferior oversizing
(not more than 10%) and the choice of the most ﬂexible device.
This concept is crucial when the haemorrhage is extended to the
proximal aortic neck. Furthermore, caution has been advised
against aggressive attempts to balloon-dilate landing zones to
avoid stent-graft erosion into the aortic wall. When treatment of
IMH in an acute stage is clinically necessary, e.g. when there is
persistent pain with medical management, severe expansion >5
mm or signs of impending rupture, anchorage of the endograft in
the noninvolved aortic wall is required. Thus, in these cases, open
surgery performed by expert groups may remain preferable.
From the acute phase, the intramural haemorrhage evolves
with ﬁbrotic changes and the aortic wall becomes more stable
after 2 months. Over 40% of cases can show complete regression
in the ﬁrst 6 months; however, a high percentage of the remainder
could evolve to classic or localized dissection and aortic aneur-
ysm. Although recommendations for surgical treatment or TEVAR
are well established and similar for cases of classic dissection or
aneurysm, many controversial points exist in the treatment of
localized dissection and ULP. While some series reported a high
risk of complications in cases of IMH with ULP, others
Figure 2: Acute and chronic management pathway for type B IMH. ULP: ulcer-like projection; MAD: maximum aortic diameter; IMH: intramural haematoma.
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demonstrated a more benign course. Although invasive treatment
was indicated due to the diagnosis of a new ULP in the majority of
cases described in the literature [31], only a few series reported
sudden death or aortic rupture related to this complication [26].
Initial depth of ULP seems to be a prognostic factor in these cases
[31, 40]. Nevertheless, the cut-off value to indicate invasive treat-
ment remains unclear. Medical treatment and close follow-up
with imaging techniques every 3 months is the recommended
management in patients with IMH and ULP without persistent
pain or signs of aortic rupture in the ﬁrst year. Thus, when ULP
size remains stable, follow-up can be made every 6 months and
annually beyond the third year. During follow-up, a ULP may
remain stable, show regression or increase in size. Invasive treat-
ment of IMH is indicated if MAD >55 mm or mean growth rate is
≥5 mm/year. Initial depth of ULP >10 mm requires a close follow-
up, and in spite of the lack of published series, values >15 mm
could be an indication of endovascular treatment. This latter
indication necessitates the measurements being repeated using
the same imaging technique, at the same aortic level, with
side-by-side comparison. Treatment by TEVAR or open surgery
should be based on the anatomical features of the lesion, patient
comorbidities, anatomical constraints related to endograft tech-
nology and experience and results of the centre in both thera-
peutic strategies. In any event, closer follow-up with imaging
techniques is necessary after TEVAR in these patients (Fig. 2).
Penetrating aortic ulcer
The ﬁrst step in choosing the correct management of an aortic
ulcer is to distinguish PAU from ULP. Usually, in the context of an
AAS, ULP is not detected in the ﬁrst imaging study, since this
Figure 3: Acute and chronic management pathway for type B PAU. IMH: intramural haematoma; PAU: penetrating atherosclerotic ulcer.
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lesion appears some days or weeks after of acute IMH. In contrast,
when a PAU is the cause of AAS, it must be diagnosed in the ﬁrst
study. Some imaging ﬁndings could aid the differential diagnosis,
e.g. the presence of atherosclerotic plaque and some morpho-
logical characteristics deﬁned by multidetector CT or transoeso-
phageal echocardiography (TEE) .
Generally, a PAU presents many irregularities in the intimal
layer, with calciﬁcation of the ulcer edges, typical of atherosclerot-
ic plaques, and could be accompanied by a haematoma localized
around the lesion. On the other hand, a ULP is detected during
the course of an IMH, and frequently appears as an image of
intimal rupture with a small intimal ﬂap. Unfortunately, differenti-
ation of the two entities is not always possible owing to the rapid
tempo of morphological evolution. Thus, depending on exactly
when an imaging ‘snapshot’ is taken after the onset of symptoms,
a ULP may be erroneously interpreted as a PAU.
Differentiation of both entities is crucial since a PAU sur-
rounded by an IMH has a higher risk of aortic rupture than an
IMH complicated with a ULP or localized dissection. A PAU with
persistent pain, with an IMH or periaortic haemorrhage must be
treated surgically or with TEVAR. In these cases, the lesion is fre-
quently localized and permits endovascular treatment without the
risk of intimal ruptures at the ends of the device. The mortality
rate in the acute phase of open surgical treatment was 15.9 vs
7.2% of TEVAR. Considering that many patients are inoperable or
run a prohibitively high open surgery risk, TEVAR may be an excel-
lent therapeutic option.
In asymptomatic patients with a non-complicated PAU, general
treatment recommendations have yet to be deﬁned owing to the
lack of reliable data concerning the natural course of the disease.
Patients with PAU often have extensive arteriosclerotic disease,
possibly including peripheral occlusive disease, which renders a
suitable TEVAR access challenging. Therefore, meticulous examin-
ation of the access vessels is mandatory to achieve safe access.
Although TEVAR has yielded favourable perioperative results, the
available mid-term outcomes underline the signiﬁcance of co-
morbidities: the 5-year survival rate is around 65% [48, 72].
Coronary artery disease, neurological complications and the risk
of endoleak should be considered. Severe coronary disease is a
common ﬁnding in patients with PAU, and cardiac complications
are frequently observed after TEVAR. Thus, meticulous preopera-
tive cardiological evaluation is warranted. Patients with thoracic
aortic disease who undergo surgical or endovascular intervention
and present symptoms or ﬁndings of myocardial ischaemia
should be studied to determine whether signiﬁcant coronary
artery disease is present. Multidetector computed tomography
coronarography or cardiac catheterization is advisable in pre-
operative evaluation of these patients. In cases of unstable coron-
ary syndromes, revascularization prior to or at the time of surgical
or endovascular aortic treatment is recommended [4]. The
reported risk of stroke is similar for TEVAR and open surgery in the
reviewed literature (4 vs 7%, respectively) [47, 60]. The use of TEE
for monitoring the procedure may minimize the risk of embolic
stroke caused by guide-wire manipulation in the presence of high-
grade atheroma of the aortic arch and prevent secondary endo-
leaks due to laminated thrombi in stent-graft landing zones.
In asymptomatic patients, without signs of aortic rupture, aortic
ulcer size and MAD must be evaluated. When an aortic ulcer
shows a mean growth rate ≥5 mm/year or MAD >55 mm, TEVAR
should be considered; however, it is imperative to assess the risk/
beneﬁts of TEVAR in relation to age and possible comorbidities. In
cases without surgical treatment criteria, follow-up every 6
months with imaging techniques for the ﬁrst 3 years and every
year thereafter is recommended (Fig. 3).
CONCLUSIONS
Endovascular repair has become the ﬁrst option in the treatment
of complicated type B aortic PAU and IMH, mainly when lesions
are localized and there are no constraints for endograft technol-
ogy. The low mortality rate in published series and the high per-
centage of good results of stent-graft repair have been the
keystones of this success. In comparison with open surgery results
at centres of excellence, TEVAR seems to be a more accessible and
less demanding treatment at centres where this technique is
usually carried out. However, owing to the lack of randomized,
controlled trials, some doubts remain, which may be resolved
with the increasing use of these techniques in coming years.
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